Research programme: neurodegenerative disorders therapeutics - Galantos Pharma

Drug Profile

Research programme: neurodegenerative disorders therapeutics - Galantos Pharma

Alternative Names: Antidementia drugs programme - Galantos Pharma; Antidementive drugs programme - Galantos Pharma

Latest Information Update: 29 Nov 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Galantos Pharma
  • Class
  • Mechanism of Action Cholinergic receptor modulators; Cholinesterase inhibitors; Nicotinic receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease; Neurodegenerative disorders

Most Recent Events

  • 15 May 2012 Discontinued - Preclinical for Alzheimer's disease in Germany (unspecified route)
  • 15 May 2012 Discontinued - Preclinical for Neurodegenerative disorders in Germany (unspecified route)
  • 29 Aug 2007 Galantos Pharma is seeking collaboration opportunities for this programme (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top